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Abstract 
 
 The engineering of responsive multifunctional delivery systems that combine therapeutic and 
diagnostic (theranostic) capabilities holds great promise and interest. We describe the design of 
thermosensitive liposome-nanoparticle (NP) hybrids that can modulate drug release in response to 
external heating stimulus. These hybrid systems were successfully engineered by the incorporation of 
gold, silver, and iron oxide NPs into the lipid bilayer of lysolipid-containing thermosensitive liposomes 
(LTSL). Structural characterization of LTSL-NP hybrids using cryo-TEM and AFM revealed the 
incorporation of metallic NPs into the lipid membranes without compromising doxorubicin loading and 
retention capability. The presence of metallic NPs in the lipid bilayer reinforced bilayer retention and 
offered a nanoparticle concentration-dependent modulation of drug release in response to external 
heating. In conclusion, LTSL-NP hybrids represent a promising versatile platform based on LTSL 
liposomes that could be further utilize the properties of the embedded NPs for multifunctional 
theranostic applications. 
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1. Introduction 
  
 Liposomes are self-assembled phospholipid vesicles that have been clinically approved as a 
nanoscale delivery system for various therapeutic applications.(Allen and Cullis, 2013; Barenholz, 
2012) Liposomes can effectively entrap both hydrophilic (Lozano et al., 2015; X et al., 1998) and 
hydrophobic compounds (Chen et al., 2010; Koudelka and Turánek, 2012; Lozano et al., 2015) in 
their aqueous core or the lipid bilayer, respectively. Liposomes are biocompatible, biodegradable and 
can effectively modify the pharmacokinetic profile of their loaded drugs(Sawant and Torchilin, 2012). 
Stealth liposomes can passively accumulate at the tumor site as they leak through malformed blood 
vessels while avoiding healthy tissues and organs (Gabizon et al., 1994; Gabizon and Martin, 1997). 
Next-generation liposomes that can trigger-release their drug content in response to external stimuli 
have been developed to improve drug bioavailability and overall therapeutic efficacy.(Al-Ahmady et 
al., 2014; Al-Ahmady et al., 2015) The most clinically advanced such vesicle system is commercially 
known as ThermoDox®, a lysolipid-containing temperature-responsive liposome (LTSL) that is 
currently in clinical trials for treatment of solid tumors in combination with mild hyperthermia (HT) (Al-
Ahmady and Kostarelos, 2016). 
 Over the last few years, advances in nanotechnology have dramatically increased interest in 
developing metallic nanoparticles (NPs) for a wide range of applications.(Grzelczak and Liz-Marzan, 
2013; Hormeno et al., 2014; Johannsen et al., 2010; Liu et al., 2012; Maestro et al., 2014; Visaria et 
al., 2006; Wong and Liu, 2010). The nanoscale size of metallic NPs such as gold (AuNPs), silver 
(AgNPs), superparamagnetic iron oxides (SPIO) and their novel optical and magnetic properties 
enable their use for both imaging and therapeutic purposes. For example, the enhanced surface 
plasmon resonance of AuNPs makes them particularly attractive for imaging and photo-thermal 
applications (Maestro et al., 2014). The absorption of light at certain wavelengths causes the 
oscillation of surface electrons and subsequent local heat generation, that can be controlled by the 
intensity of the laser beam irradiation, duration of NP exposure and the concentration of AuNPs 
(Alkilany et al., 2012).  
 Similarly, SPIO NPs have been used extensively as a contrast agent for magnetic resonance 
imaging (MRI). The magnetic properties of SPIO NPs can also be exploited for the generation of 
magnetically-mediated hyperthermia (Chanda et al., 2010). The exposure of SPIO NPs to an 
alternating magnetic field can generate high local heating by Neel fluctuations which have showed 
potential in cancer therapy (Jordan et al., 2006; Maier-Hauff et al., 2007). NP-induced hyperthermia 
has the potential to overcome some of the limitations of conventional heating techniques when 
treating deep or non-accessible tumors (Preiss and Bothun, 2011). However, the inherent hydrophobic 
surface character of metallic NPs and their limited colloidal stability can significantly affect their 
biological performance.  
 We and others have previously shown the possibility of using liposome technology as a 
delivery platform that could allow the incorporation of metallic NPs (Al-Jamal et al., 2008; Jain et al., 
2003; Lozano et al., 2012). Liposomal incorporation of metallic NPs has proved to be an effective way 
to increase nanoparticle stability and biocompatibility in biological conditions (Lozano et al., 2012; 
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Preiss and Bothun, 2011). This can be achieved by either the incorporation of hydrophobic NPs within 
the lipid membrane or encapsulation of the hydrophilic NPs in the liposomal aqueous core (Tai et al., 
2009). Alternatively, metallic NPs can be functionalized onto the liposomal surface by either physical 
or chemical conjugation (Chithrani et al., 2010; Pornpattananangkul et al., 2010). To date several 
examples of liposome-NP hybrids have been designed for diagnostic (Soga et al., 2010), or simply for 
colloidal stabilization (Kojima et al., 2008; Lozano et al., 2012) purposes, with some interesting 
examples of smart hybrid systems that can trigger release in response to external stimuli. Such cases 
of thermosensitive liposome-NP hybrids were designed to utilize the photonic and electromagnetic 
properties of NPs for local heat generation and triggered content release (Paasonen et al., 2010; Tai 
et al., 2009; Wu, 2008). As a proof of concept, several studies have demonstrated the release of 
encapsulated dye molecules from such hybrid systems (Bealle et al., 2012; Chen et al., 2010; 
Paasonen et al., 2010). However, only a few studies have reported the potential of combining 
thermosensitive liposome-NP hybrids with therapeutic agents for combinatory therapeutic and 
diagnostic applications (Tian et al., 2011). 
 The aim of the present work was to engineer and characterize doxorubicin loaded-
thermosensitive, liposome-NP hybrids as multimodal smart systems to control drug release. Drug 
(doxorubicin) loaded, LTSL were chosen for this study as the most advanced TSL that are currently in 
clinical trials (Clesion.com, 2016; Landon et al., 2011). The incorporation of three different types of 
metallic NPs into LTSL was studied and the capacity of the hybrid systems to modulate drug release 
was investigated. 
2. Materials and Methods 
 
Materials.1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1-stearoyl-2-hydroxy-sn-glycero-3-
phosphocholine (MSPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-2000] (DSPE-PEG2000 ) were kind gifts from Lipoid GmbH (Ludwigshafen, Germany). 
Ammonium sulfate, sodium hydroxide, chloroform and methanol were purchased from Fisher 
Scientific. 1,6-Diphenyl-l,3,5-hexatriene (DPH) was purchased from Invitrogen. Diethyl ether, 
doxorubicin hydrochloride (DOX), 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES), 
sodium chloride (NaCl), Sephadex® G-50, oleic acid-functionalized magnetic SPIO NPs solution 
5mg/mL in toluene, octanethiol-functionalized AuNPs 2% solution in toluene, decanethiol-
functionalized AgNPs 0.1% (w/v) in hexane, 8-anilino-1-naphthalenesulfonic acid (ANS), and 
tetrahydrofuran were purchased from Sigma.  
 
Preparation and Characterization of Liposomes and Liposome-NP Hybrids. Lysolipid containing 
temperature-sensitive liposomes (LTSL) composed of DPPC:MSPC:DSPE-PEG2000 86:10:4 (molar 
ratio) were prepared using the reverse phase evaporation method [RP] and the lipid film-reverse 
phase evaporation method [F-RP] (Figure 1 A). For the RP method the lipids dissolved in 
chloroform/methanol mixture were mixed in 25ml round bottom flask and then 6ml of 
chloroform/diethylether (1:1, v/v) and 1.5ml of 240mM ammonium sulfate buffer (pH 5.4) were added 
at 1:4 v/v (aqueous/organic). In order to form w/o emulsion, the mixture was sonicated for 15min in a 
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bath sonicator at 40°C. Organic solvents were then evaporated using rotary evaporator (BÜCHI, 
Switzerland) at 460mbar and 40°C for 2h resulting in the formation of a gel-like phase followed by 
aqueous phase formation. Large unilamellar liposomes (LUVs) formed by this process were then 
reduced in size by 30min sonication at 60°C using a bath sonicator.  
To prepare the liposomes by F-RP method, the same procedure described above was applied 
with the exception that a lipid film was first prepared by evaporating chloroform:methanol from the 
lipid mixture. This then followed by re-dissolving the lipid film in the chloroform/diethylether/ammonium 
sulfate mixture as described earlier. 
For the preparation of liposome-NP hybrids, F-RP method was applied. First, the exact 
amount of hydrophobic NPs dispersion (5µg or 10µg) was added to 25ml round bottom flask. The 
organic solvent in which the NPs were dispersed was removed using rotary evaporator at 6mbar and 
40°C for 1h. The lipids mixture of DPPC:MSPC:DSPE-PEG2000 86:10:4 (molar ratio) dissolved in 
chloroform/methanol (4:1) were then added and the organic solvents were evaporated to form the 
lipid film containing the NPs. The resulting lipid film was then re-dissolved the lipid film in 6ml of 
chloroform/diethylether (1:1). Following this step 1.5ml of 240mM ammonium sulfate buffer (pH5.4) 
was added and the mixture was sonicated for 15min in a bath sonicator at 40°C. Organic solvents 
were then evaporated using rotary evaporator at 460mbar and 40°C for 2h and the size of LUVs of 
LTSL-Np hybrids was then reduced by bath sonication as described earlier.  
Liposome size and surface charge were measured by using Zetasizer Nano ZS (Malvern, 
Instruments, UK). For size measurement samples were diluted with HEPES buffer saline (HBS) 
composed of 20mM HEPES, 150mM NaCl, pH 7.4 and measured in 1ml cuvettes. Zeta potential was 
measured in disposable Zetasizer cuvettes and sample dilution was performed with distilled water.  
 
Cryo-Transmission Electron Microscopy (Cryo-TEM). Visualization of samples with Cryo-TEM was 
performed to study the morphology of LTSL-NPs hybrids and to confirm the incorporation of metallic 
NPs. Sample preparation was carried out in a temperature- and humidity-controlled chamber using a 
fully automated (PC-controlled) vitriﬁcation robot (Vitrobot). 46 A specimen grid was dipped into a 
suspension and withdrawn, and excess liquid was blotted away. Thin ﬁlms were formed between the 
bars of the grids. To vitrify these thin ﬁlms, the grid was shot into melting ethane. The grids with 
vitriﬁed thin ﬁlms were analyzed in a CM-12 transmission microscope (Philips, Eindhoven, The 
Netherlands) at 170°C using a Gatan-626 cryo-specimen holder and cryotransfer system (Gatan, 
Warrendale, PA). The vitriﬁed ﬁlms were studied at 120kV and at standard low-dose conditions.  
 
Atomic Force Microscopy (AFM). Sample analysis with AFM was then performed to study the effect 
of NPs incorporation on the bilayer thickness. 20μl of liposome dispersion in a concentration of 5mM 
was deposited on the surface of a newly cleaved mica sheet (Agar Scientific, Essex, UK) and was 
allowed to adsorb for 1min. Unbound liposomes were washed out by filtered distilled water and then 
dried by dust-free compress air. Images were taken in tapping-mode using a Multimode AFM, E-type 
scanner, Nanoscope IV controller with Nanoscope 5.31r1 control software (Bruker Surface Nano, 
Cambridge, UK). The tip was a silicon tapping tip with 10nm curvature radius (NSG01, NTI-Eutope, 
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Apdldoorn, The Netherlands). Typical resonant frequency of the tapping-mode silicon cantilever of 
150kHz with a force constant of 5.5N/m was used. A scan rate of 1Hz was used to scan a 5μm2 of the 
mica surface with a resolution of 512 × 512 pixels. WSxM 5.0 software was used to process, filter and 
flatten the images. 
 
Differential Scanning Calorimetry (DSC). Phase transition temperature (Tt), of LTSL Liposomes and 
the three types of LTSL-NP hybrids were studied with DSC. This method is use to study the change in 
bilayer structure from solid gel-phase into liquid crystalline-phase as the temperature increased. 
Liposomes were prepared as LUVs by F-RP method. Samples were first prepared at the 
concentration of 15mM and then concentrated 5 times by centrifugation at 13,000rpm for 30min using 
0.22μm Spin-X Centrifuge Tube Filters (Sigma-Aldrich, UK). 20μl of the concentrated liposome 
dispersion were then transferred and sealed into the hermetic Tzero™ DSC pan and analyzed by 
Q2000 DSC (TA Instruments, USA) at 1°C per min from 30°C to 60°C. 
 
Fluorescence Anisotropy Measurements. Fluorescence anisotropy experiments were performed to 
study the effect of metallic NPs incorporation on the liposomes membrane fluidity. A hydrophobic 
probe (DPH) and hydrophilic probe (ANS) were used to monitor the changes in the bilayer fluidity at 
the hydrophobic region of the lipid membrane and near the liposomes surface, respectively. 
Experiments were performed as previously described.(Al-Ahmady et al., 2012) Briefly, liposomes were 
further diluted to 0.025mM and divided into two 4ml aliquots. DPH solution in tetrahydrofuran (0.8mM, 
2.5µl) or an aqueous ANS solution (10mM, 4µl) was mixed with the liposomes at 500:1 lipid/DPH or 
25:1 lipid/ANS. To allow the probes to be incorporated, the samples were shaken at room temperature 
for 2h and then left overnight before starting measurements. Fluorescence polarization was then 
measured by a LS-50B spectrofluorometer (Perkin Elmer) equipped with automated polarizer and 
thermostatic cell holder connected to a water bath to control the sample temperature. For the DPH 
experiment, the anisotropy measurements were carried out at an excitation wavelength of 395nm (slit 
of 10nm) and emission wavelength of 476nm (slit of 5nm). Measurements were started at 25oC, and 
then the temperature was increased gradually up to 60oC. Boltzmann curve fitting of the experimental 
values were performed using Origin software. The samples were equilibrated for at least 6min after 
each temperature change. Fluorescence anisotropy was then measured automatically by the 
spectrofluorometer based on equation (1); 
r =  
Ivv−GIvH
Ivv+2GIvH
        (1) 
where r is the fluorescence anisotropy and IVV and IVH are the emission intensity excited with 
vertically polarized light and measured with emission polarizer oriented in a parallel or perpendicular 
direction to the plane of excitation, respectively. G is an instrument specific factor calculated to correct 
the instrument polarization, which is equal to IHV/IHH, and obtained by measuring the vertically and 
horizontally polarized emission intensities after excitation with horizontally polarized light. 
Doxorubicin Loading Using pH-Gradient Method. Remote doxorubicin loading into pre-formed 
liposomes was performed using pH gradient method. Ammonium sulfate buffer 240mM (pH 5.4) was 
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used for the liposomes preparation as mentioned earlier then external buffer exchange was performed 
by gel filtration through Sephadex® G-50 column equilibrated with HBS (pH 7.4). Doxorubicin 
hydrochloride (5mg/ml) was added to the liposome suspensions at 20:1 lipid/doxorubicin mass ratio 
(i.e. 0.187 mg of doxorubicin for 5mM liposomes). This was then followed by 2h incubation at 37°C.  
 After incubation liposomes were passed again through Sephadex® G-50 column to remove 
any free doxorubicin. Encapsulation efficiency (% EE) was calculated by comparing the total 
fluorescence intensity of doxorubicin post and pre gel filtration, diluted to the same final lipid 
concentration using equation (2);  
% EE= I(t) post column / I(t) pre column *100         (2) 
where, I(t) is the total fluorescence intensity of the liposome suspension after adding 2 µl Triton X-100 
(10% in HBS, pH 7.4).  
 
Doxorubicin Release studies: 
Doxorubicin release was measured by taking advantage of the fluorescence quenching process. 
When doxorubicin is encapsulated inside the liposomes, its concentrations is very high resulting in 
self-quenching of the fluorescence signal. When the ambient temperature exceeded the liposome Tt, 
doxorubicin was released from the liposomes and its concentration is diluted resulting in increase in 
fluorescence intensity, which is used to monitor the release process.  
 Doxorubicin release studies were performed in HBS. Samples were incubated at 37°C and 
42°C with a shaking water bath (Grant, U.K.). 20µl Samples were then measured at different time points 
at 480/595nm excitation and emission wavelengths (slit 15/20nm) using PerkinElmer Luminescence 
Fluorimeter (LS50B). The intensity of the fluorescence signals was then normalized and the % of 
doxorubicin release was calculated using equation (3); 
% Release = [I(s) – I(0)]/[I(t) – I(0)] * 100           (3) 
Where, I(s) is the fluorescence intensity of individual samples at different time points, I(0) is the 
background fluorescence intensity of liposome samples after purification and I(t) is the fluorescence 
intensity of liposomes suspension after the addition of 2µl of 10% Triton X-100 in HBS (pH 7.4). 
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3. Results 
Engineering Thermosensitive Liposome-NPs Hybrids. Thermosensitive liposome-NP hybrids were 
engineered using the reverse phase evaporation method (Szoka and Papahadjopoulos, 1978) based 
on the hypothesis that significantly higher NP incorporation within the lipid bilayer would be afforded. 
To test this, two alternative reverse phase evaporation-based protocols were compared, namely, the 
original reverse phase evaporation [RP] and the modified lipid film hydration-reverse phase 
evaporation [F-RP], aiming to maintain the thermal sensitivity of the lysolipid-containing LTSL (Figure 
1A). 
 First, plain LTSL liposomes were prepared by both RP and F-RP that did not show a 
significant difference in mean vesicle diameter and surface properties (Figure 1 B). However, 
fluorescence anisotropy studies and a doxorubicin release experiment indicated significant 
differences between the two protocols. Fluorescence anisotropy studies were performed using two 
different types of membrane-bound probes (DPH and ANS) to allow monitoring of the molecular 
interactions at the alkyl chain and head group regions of the vesicle bilayer, respectively. Higher 
anisotropy values were observed from LTSL liposomes prepared with the RP protocol, indicating an 
increase in bilayer rigidity compared to the F-RP protocol (Figure 1Ci, ii). This was also associated 
with a reduction in the temperature-responsiveness of the LTSL-RP illustrated by the limited 
doxorubicin release after 60min of exposure to mild HT (42°C). In comparison, LTSL liposomes 
prepared with F-RP protocol preserved their thermo-responsiveness evidenced by complete drug 
content release (> 90% release) at 42°C (Figure 1C. iv).  
 Based on the above and in order to preserve the thermal sensitivity of LTSL liposomes, the F-
RP protocol was chosen for the engineering of the LTSL-NP hybrid vesicles. Thermosensitive 
liposome-NP hybrids were designed to incorporate the metallic NPs within the phospholipids bilayer. 
Three different types of metallic NPs were studied: AuNPs, AgNPs and SPIO NPs. In order to ensure 
that the NPs were embedded in the lipid bilayer, hydrophobic NPs with a size that is comparable to, or 
smaller than the thickness of a lipid membrane (<5 nm) were selected (Figure 2A) (Al-Jamal et al., 
2008). 
 
Cryo-TEM and AFM Imaging of Thermosensitive Liposome-NP Hybrids. The incorporation of all 
three types of metallic NP into LTSL vesicle bilayers by the F-RP method was performed and the 
morphological characterization of the ensuing hybrid systems was studied by cryo-TEM and AFM. 
Although the exact quantification of metallic NPs embedded in the liposomes was not quantified, we 
have studied the interaction between metallic NP within the LTSL vesicles using cryo-TEM and AFM 
imaging. LTSL-NPs hybrids imaged by cryo-TEM, indicated that the incorporation of the NP into the 
lipid bilayer was taking place (Figure 2B, see arrows). Surface topology of LTSL-NP hybrids was also 
studied with AFM. Interestingly, AFM cross-section analysis (Figure 2C). suggested that metallic NP 
incorporation into LTSL increased the height (i.e. thickness) of the lipid bilayer from 6-8 nm to almost 
18-20 nm. This was in agreement with previously reported studies from other liposome hybrid 
systems (Tian et al., 2011). Overall, the microscopy evidence obtained by cryo-TEM and AFM 
corroborated to suggest that the metallic NPs were localized within the lipid bilayers. 
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The Effect of NP Concentration on Hybrid System Properties. To study the effect of the 
incorporated NP concentration on the properties of LTSL hybrid systems, AuNP were chosen as it is 
considered the most popular NP for efficient light induced heating and attracted great attention in the 
past for their multifunctional character. Two different concentrations of AuNPs were selected for these 
studies; 5 and 10μg/ml. Incorporation of AuNP at both concentrations resulted in hybrid systems less 
than 100nm in mean diameter, low polydispersity index (PDI) and a slightly negative surface charge 
(Figure 3A). Fluorescence anisotropy studies showed higher r values for the LTSL-AuNP hybrids 
(compared to LTSL alone) indicating an increase in bilayer rigidity by the incorporation of AuNPs 
(Figure 3Bi, ii). LTSL-AuNP hybrids were successfully loaded with the anticancer drug doxorubicin 
and maintained good stability at body temperature as evidenced by drug retention at 37°C (Figure 
3Ciii). Interestingly, a concentration-dependent modulation of doxorubicin release at mild HT (42°C) 
was observed by the incorporation of AuNP within the LTSL bilayers (Figure 3Civ), that could be 
expected as a result of the anisotropy-determined increase in bilayer rigidity. 
 
The Effect of Metal NP Type on Hybrid System Properties. The effect of NP type on the hybrid 
vesicle characteristics and temperature-triggered release properties was investigated next. Three 
different types of metallic NPs were compared by allowing their incorporation into LTSL lipid bilayers 
at 10µg/ml using the F-RP protocol. Physicochemical characterization of LTSL-AuNP/AgNP/SPIO 
hybrid systems revealed that all LTSL-NP hybrids resulted in mean vesicle diameter (and PDI) 
comparable to LTSL alone (Figure 4A). It is also worth noting that the bilayer Tt after incorporation of 
the three different metallic NPs remained consistent with that of the LTSL alone (between 40.5-41°C). 
The three types of LTSL-NP hybrid vesicles were found to be more surface charge neutral than their 
plain LTSL liposome counterpart. Interestingly, all LTSL-NP hybrid systems were able to be remote-
loaded with doxorubicin at a higher encapsulation efficiency compared to LTSL liposomes prepared 
by F-RP. The encapsulation efficiency of all tested were almost comparable to what observed from 
LTSL-RP. The presence of NPs in the lipid bilayer of LTSL liposomes prepared by F-RP method may 
offer better preservation of the pH gradient required for doxorubicin loading process. This could be 
due to the increase in bilayer rigidity in the presence of NPs compared to plain LTSL. As observed 
from florescence anisotropy studies. This again indicated that the incorporation of metallic NPs into 
LTSL lipid bilayers resulted in a higher bilayer rigidity revealed by an increase in r values (Figure 4Bi, 
ii), which was almost comparable to r values observed before from LTSL-RP (Figure 1C i). This 
increase in bilayer rigidity was observed both in the core and head group region of the phospholipid 
membrane irrespective to the type of the NPs incorporated, even though it did not lead to a change in 
the overall Tt of the bilayer as noted above. In terms of doxorubicin release profile, similar to LTSL-
AuNP hybrids described above, LTSL-AgNP and LTSL-SPIO hybrids maintained good drug retention 
at body temperature (Figure 4Biii), while offering controlled drug release for 60min under mild HT 
conditions (Figure 4Biv). All three types of LTSL-NP hybrids released doxorubicin at significantly 
lower rates compared to the LTSL liposomes. Overall, no significant differences were observed in 
both physicochemical and drug release characteristics among the three different types of LTSL-NP 
hybrids, in contrast to the sharp differences in comparison to LTSL liposomes alone. 
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4. Discussion 
 
 Even though liposomes and metallic NPs are independently already in clinical practice, the 
combination of liposome-NP hybrids is still an exploratory approach to design a new generation of 
multifunctional delivery systems (Preiss and Bothun, 2011). The aim of such hybrid systems is to 
combine the capabilities of both liposomes and NPs and therefore provide an advanced platform for 
theranostic applications. Thermosensitive liposome-NP hybrid systems are interesting examples of 
such design strategies as they aim to take advantage of the thermal properties of NPs in order to 
achieve remote drug release (Pradhan et al., 2010; Volodkin et al., 2009). Several examples of 
thermosensitive liposome-NP hybrids have been proposed recently by incorporating NPs either in the 
aqueous core, lipid membrane or by surface adsorption. From these three different designs, 
membrane-embedded and surface-adsorbed NPs showed the highest content release. This effect 
was studied in detail by Passonen et al. by incorporating 2-4nm AuNPs into DPPC:DSPC TSL to 
report the percentage of calcein release after 5-10min of continuous exposure to UV light at 250nm 
(Paasonen et al., 2007). Maximum release was achieved from membrane embedded Au-C6SH NPs 
and surface adsorbed DPPE-NanoAu® NPs. Similarly, the extent of carboxyfluorescein dye release 
from DPPC liposomes decorated with hollow Au nanoshells(Wu, 2008) and DPPC:DPTAP:CHOL-
AuNPs complexes (Volodkin et al., 2009) was highly dependent on the proximity of the NPs to the 
lipid bilayer. The reason behind that was possibly due to a more efficient and localized direct heat 
transport from the NPs to the liposomal bilayer compared to the encapsulated AuNPs (Paasonen et 
al., 2007). These results also suggested that the mechanism behind the observed triggered release 
could be due to the formation of transient pores in the bilayer or due to other forms of mechanical 
disruption of the lipid bilayer by the incorporated NPs. Fluorescence anisotropy has also been widely 
used to study the effect of NPs incorporation on lipid membrane packing and fluidity, showing that this 
is largely dependent on the concentration, size, position of NPs incorporated and the temperature 
tested (Park et al., 2005, 2006; Park et al., 2009). 
 In agreement with our findings, incorporation of small hydrophobic NPs (<5nm) decreased the 
lipid membrane fluidity (membrane rigidifying effect) particularly at temperatures below the phase 
transition temperature of the lipid membrane (Park et al., 2005, 2006; Park et al., 2009). Membrane 
rigidity was augmented with increasing the NP concentration. The most likely explanation for such 
effects is the small size of NPs (smaller than the thickness of bilayer) that allows for complete NP 
incorporation within the lipid bilayer (Park et al., 2005, 2006; Park et al., 2009). Increased bilayer 
rigidity can also explain the different rates of drug release observed from the three types of liposome-
NP hybrids we studied here. This observation also agreed with a previous report by Chen et al. who 
showed that the release of an encapsulated dye molecule (5,6-Carboxyfluorescein) from DPPC 
liposomes was reduced by increasing the amount of SPIO NPs embedded within the lipid membrane 
(Chen et al., 2010). Interestingly, that study also showed that content leakage was enhanced when 
triggered by an external magnetic field, further suggesting the critical role played by the incorporated 
NPs (Chen et al., 2010). The opposite effect on lipid membrane rigidity was observed when the 
incorporated NPs were near or just exceeding the thickness of the lipid membrane. Increases in 
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DPPC membrane fluidity and a decreased vesicle phase transition temperature were reported by the 
incorporation of AgNPs larger than 5nm.(Bothun, 2008) The distortion of the lipid bilayer to 
accommodate the NPs was suggested as responsible for the decrease in lipid ordering and increased 
membrane fluidity (Bothun, 2008). No significant effect on bilayer fluidity was reported from NPs 
encapsulated in the aqueous core (Bothun, 2008; Preiss and Bothun, 2011). 
 Despite previous reports of interesting new designs of thermosensitive liposome-NP hybrids, 
only a few studies have investigated the therapeutic relevance of these systems by the encapsulation 
of clinically-used drug molecules. These examples involved the co-encapsulation of both therapeutic 
drug molecules, such as doxorubicin (Pradhan et al., 2010) or methotrexate (Zhu et al., 2009), and 
metallic NPs in the liposomal aqueous compartment and showed interesting effects in response to 
external stimuli (Pradhan et al., 2010; Zhu et al., 2009).  
The capability of combining therapeutic and imaging functionalities in a single liposome-NP 
hybrid system can provide an attractive theranostic approach for many diseases in which both 
diagnosis and therapy need to be combined. Such hybrid systems can be imaged to offer non-
invasive assessment blood kinetics and tissue distribution, targeted at specific cells and tissue, as 
well as offer controlled drug release at the target site on external stimulation. Consequently, this would 
provide the potential to have better prediction of the therapeutic activity and open new insights into 
more personalized medications. In the present study, we reported thermosensitive liposome-NP 
hybrid systems by incorporating different types of metallic NPs in the bilayer of clinically-developed 
LTSL formulations. Altering the concentration and the type of the NPs we can effectively control drug 
release from LTSL liposomes without interference with drug loading and drug retention. LTSL-NP 
hybrid systems present a potential multifunctional vector of great modular capacity, whose properties 
can be modulated by the type of NPs incorporated within the lipid bilayer. 
More research is warranted to optimize the choice of TSL formulation and biocompatibility of 
the liposome-NP hybrids. In addition, the structural integrity of the liposome-NP hybrids in vivo needs 
to be further investigated to address the possibility of NP release from liposomes during blood 
circulation and the consequences this could have on drug retention, drug pharmacology and long 
term safety profile. Furthermore, the therapeutic and imaging potential of liposome-NP hybrids needs 
to be further explored using clinically relevant non-invasive external triggering techniques.  
  
5. Conclusions 
In conclusion, we present the engineering of doxorubicin-loaded thermosensitive liposome-
NPs hybrids as potential theranostic platforms. The use of metallic NPs with mean diameters smaller 
than the thickness of lipid membrane ensured successful incorporation within the vesicle lipid bilayer 
as evidenced with cryoTEM and AFM studies. As a result of that an increase in bilayer rigidity and 
tunable doxorubicin release profile from the hybrid systems was obtained after heating. Our data 
suggested that this approach can provide an alternative strategy to design stable liposome-NP 
hybrids with additional functionalities that are contributed by the type of metallic NPs incorporated. We 
suggest that LTSL-NP hybrids may offer multifunctional delivery systems with the potential to achieve 
simultaneous tracking and triggered-release.  
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Figures Legends 
 
Figure 1: (A) Schematic of the protocols used for LTSL preparation: reverse phase evaporation [RP] 
and film-reverse phase evaporation [F-RP]. (B) Colloidal stability summary and doxorubicin 
encapsulation efficiency (EE%) of the LTSL prepared by [RP] and [F-RP]. Data obtained by Nanosizer 
ZS and fluorescence spectrophotometer. (C) Effect of LTSL preparation protocol: fluorescence 
anisotropy values of (i) DPH and (ii) ANS and % doxorubicin released at (iii) 37°C and (iv) 42°C 
using the [RP] (squares and solid lines) and [F-RP] (circles and dashed lines) protocols. 
 
Figure 2: (A) Hydrophobic NPs characteristics. (B) Cryo-TEM micrographs showing the morphology 
and incorporation of metallic NPs in the lipid bilayer of the liposomes as indicated by the arrows, and 
(C) AFM (amplitude and 3D images and cross-section analysis) for 5mM LTSL without and with 10 
μg/mL of AuNPs, AgNPs and SPIO NPs. 
 
Figure 3: (A) Colloidal stability summary and doxorubicin encapsulation efficiency (EE%) of LTSL and 
LTSL-AuNP hybrids. Data obtained by Nanosizer ZS and fluorescence spectrophotometer.  
(B) Fluorescence anisotropy of (i) DPH and (ii) ANS and % doxorubicin released at (iii) 37°C and (iv) 
42°C for 5mM LTSL (squares and solid lines) and LTSL embedded with 5 (circles and dashed lines) 
and 10 (up-triangles and dotted lines) µg/ml of AuNPs. 
 
Figure 4: (A) Colloidal stability summary and doxorubicin encapsulation efficiency (EE%) of LTSL and 
LTSLNP hybrids. Data obtained by Nanosizer ZS and fluorescence spectrophotometer. (B) 
Fluorescence anisotropy of (i) DPH and (ii) ANS and 1h % doxorubicin released at (iii) 37°C and (iv) 
42°C for 5mM LTSL (squares and solid lines) and LTSL embedded with 10µg/ml of AuNPs (circles), 
AgNPs (up-triangles), and SPIO NPs (down-triangles). 
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Figure 1 
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*
 Concentration of LTSL (low thermosensitive liposomes) of 5mM.
a
 Mean ± standard deviation; n = 3. 
b
 Encapsulation efficacy (EE%) of doxorubicin 2h after incubation at 37
o
C.
i ii
iii iv
C
25 30 35 40 45 50 55 60
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
r D
P
H
 v
a
lu
e
T (
o
C)
LTSL:
 [RP]       ( )
 [F-RP]    ( )
25 30 35 40 45 50 55 60
0.06
0.08
0.10
0.12
0.14
0.16
0.18
0.20
0.22
r A
N
S
 v
a
lu
e
T (
o
C)
LTSL:
 [RP]    ( )
 [F-RP] ( )
0 10 20 30 40 50 60
0
20
40
60
80
100
%
 D
O
X
 R
e
le
a
s
e
d
a
t 
3
7
o
C
Time (min)
LTSL:
 [RP]
 [F-RP]
0 10 20 30 40 50 60
0
20
40
60
80
100
%
 D
O
X
 R
e
le
a
s
e
d
a
t 
4
2
o
C
Time (min)
LTSL:
 [RP]
 [F-RP]
17 
 
Figure 2 
 
  
18 
 
Figure 3 
 
 
  
A System * Hydrodinamic diameter a  (nm) PDI a ζ-Potential a (mV) EE b  %
LTSL-5µg/mL AuNP 81.1 ± 1.7 0.277 ± 0.022 -11.6 ± 1.9 81
LTSL-10µg/mL AuNP 85.7 ± 0.4 0.272 ± 0.006 -7.1 ± 1.1 82
*
 Concentration of LTSL (low thermosensitive liposomes) [F-RP] of 5mM.
a
 Mean ± standard deviation; n = 3. 
b
 Encapsulation efficacy (EE%) of doxorubicin 2h after incubation at 37
o
C.
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Figure 4 
 
 
A System * Hydrodinamic diameter a  (nm) PDI a ζ-Potential a (mV) T t (
o
C) EE
b
 %
LTSL 73.0 ± 0.6 0.304 ± 0.032 -18.8 ± 0.1 40.98 ± 0.03 66
LTSL-AuNP 85.7 ± 0.4 0.272 ± 0.006 -7.1 ± 1.1 40.49 ± 0.08 82
LTSL- AgNP 89.6 ± 4.6 0.344 ± 0.007 -6.6 ± 0.5 40.67 ± 0.12 90
LTSL- SPIO 74.8 ± 0.3 0.245 ± 0.009 -7.1 ± 0.1 41.04 ± 0.09 83
*
 Concentration of LTSL (low thermosensitive liposomes) [F-RP] of 5mM. Concentration of nanoparticles 10µg/mL.
a
 Mean ± standard deviation; n = 3. 
b
 Encapsulation efficacy (EE%) of doxorubicin 2h after incubation at 37
o
C.
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